Trial Profile
A Single-site, Open-label, Fixed-sequence Phase 1 Study Evaluating the Effect of Eliglustat (Genz-112638) on the Pharmacokinetics and Safety and Tolerability of Digoxin in Healthy Adult Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Digoxin (Primary) ; Eliglustat (Primary)
- Indications Arrhythmias; Lysosomal storage diseases
- Focus Pharmacokinetics
- Sponsors Genzyme Corporation
- 06 Apr 2012 Actual end date (Nov 2011) added as reported by ClinicalTrials.gov.
- 06 Apr 2012 Actual initiation date changed from May 2011 to Aug 2011 as reported by ClinicalTrials.gov.
- 06 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.